Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in hemodialysis patients

International Journal of Laboratory Hematology

Volumn 38, Issue 4, 2016, Pages 360-365

  Urrechaga, E ^a   Boveda, O ^a   Aguayo, F J ^b   de la Hera, P ^b   Munoz R I ^a   Gallardo, I ^a   Escanero, J F ^c  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Erythropoiesis; hemodialysis; hypochromic erythrocytes; Iron availability; reticulocyte hemoglobin content

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HEMATOLOGY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAINTENANCE THERAPY; MALE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETICULOCYTE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84978371378     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12496     Document Type: Article

References (35)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet 2013;9888:260–72.
2. NICE guidelines Anaemia Management in Chronic Kidney Disease–Rapid Update 2011. National Clinical Guideline Centre; 2011.
3. Eckardt KU. Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes? Nat Rev Nephrol 2010;6:566–8.
4. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6:93–102.
5. NKF-K/DOQI. IV. Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;1(Suppl. 1):S182–238.
6. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl. 3):S11–145.
7. Mast A. The clinical utility of peripheral blood tests in the diagnosis of iron deficiency anemia. Bloodline 2001;1:7–9.
8. Coyne D. Iron indices: what do they really mean? Kidney Int Supl 2006;101:S4–8.
9. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:S4–8.
10. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, Chamberlin JS, Sullivan LA, Bray KR, Southwick PC. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86:923–7.
11. Macdougall IC, Cavill I, Hulme B, Bain B, Mcgregor E, Mckay P, Sanders E, Coles GA, Williams JD. Detection of functional iron-deficiency during erythropoietin treatment – a new approach. BMJ 1992;304:225–6.
12. Navarro JF, Macia ML. Hypochromic red cells as an indicator of iron deficiency. J Rheumatol 1997;24:804–5.
13. Locateli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl. 2):1–47.
14. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471–530.
15. Buttarello M, Temporin V, Ceravolo R, Farina G, Burian P. The new reticulocyte parameter RET Y of the Sysmex XE 2100. Its use in the diagnosis and monitoring of post treatment sideropenic anemia. Am J Clin Pathol 2004;121:489–95.
16. Thomas L, Franck S, Messinger M, Linssen J, Thome M, Thomas C. Reticulocyte hemoglobin measurement – comparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005;43:1193–202.
17. Garzia M, Di Mario A, Ferraro E, Tazza L, Rossi E, Luciani G, Zini G. Reticulocyte Hemoglobin Equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Haematol 2007;13:6–11.
18. David O, Grillo A, Ceoloni B, Cavallo F, Podda G, Biancotti PP, Bergamo D, Canavese C. Analysis of red cell parameters on the Sysmex XE 2100 and Advia120 in iron deficiency and in uraemic chronic disease. Scand J Clin Lab Invest 2006;66:113–20.
19. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte haemoglobin content. Am J Hematol 2008;83:307–10.
20. Urrechaga E, Borque L, Escanero JF. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin Chem Lab Med 2009;47:1411–6.
21. Buttarello M, Pajola R, Novello E, Rebeschini M, Cantaro S, Oliosi F, Naso A, Plebani M. Diagnosis of iron deficiency in patients undergoing HD. Am J Clin Pathol 2010;133:949–54.
22. Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as potential marker of iron availability. ClinChem Lab Med 2012;50:685–7.
23. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol 2013;35:144–9.
24. Briggs C, Longair I, Kumar P, Singh D, Machin SJ. Performance evaluation of the Sysmex haematology XN modular system. J Clin Pathol 2012;65:1024–30.
25. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI Study. Am J Medicine 2012;125:991–9.
26. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, Kushnir T, Girelli D, Campostrini N, Fibach E, Goitein O. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Hematol 2012;89:87–9.
27. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a metaanalysis. Am J Nephrol 2014;39:130–41.
28. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015;90:12–23.
29. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015;87:162–8.
30. Ermens AAM, Hoffmann JJML, Krockenberger M, Van Wijk EM. New erythrocyte and reticulocyte parameters on CELL-DYN Sapphire; analytical and preanalytical aspects. Int J Lab Hematol 2012;34:274–82.
31. Kim JM, Ihm CH, Kim HJ. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients. Int J Lab Hematol 2008;30:46–52.
32. Miwa N, Akiba T, Kimata N, Hamaguchi Y, Arakawa Y, Tamura T, Nitta K, Tsuchiya K. Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. Int J Lab Hematol 2010;32:248–55.
33. Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Möller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human. Ann Hematol 2005;84:159–66.
34. Fusaro M, Munaretto G, Spinello M, Rebeschini M, Amici G, Gallieni M, Piccoli A. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol 2005;18:72–9.
35. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823–4.